$CRXX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in EPIRUS Biopharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in EPIRUS Biopharmaceuticals, Inc.. Get notifications about new insider transactions in EPIRUS Biopharmaceuticals, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 31 2016 | CRXX | EPIRUS Biopharmace ... | Shea Thomas A. | Chief Financial Off ... | Option Exercise | A | 0.00 | 230,000 | 0 | 230,000 | |
May 31 2016 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | President and COO | Option Exercise | A | 0.00 | 280,000 | 0 | 280,000 | |
May 31 2016 | CRXX | EPIRUS Biopharmace ... | Aurentz Vincent | Chief Business Offi ... | Option Exercise | A | 0.00 | 230,000 | 0 | 230,000 | |
May 31 2016 | CRXX | EPIRUS Biopharmace ... | Ticktin Robert | General Counsel | Option Exercise | A | 0.00 | 230,000 | 0 | 230,000 | |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Ticktin Robert | General Counsel | Option Exercise | M | 0.00 | 2,134 | 0 | 6,400 | |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Ticktin Robert | General Counsel | Option Exercise | M | 0.00 | 949 | 0 | 0 | |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Ticktin Robert | General Counsel | Buy | M | 0.00 | 2,134 | 0 | 6,083 | 3.9 K to 6.1 K (+54.04 %) |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Ticktin Robert | General Counsel | Buy | M | 0.00 | 949 | 0 | 3,949 | 3 K to 3.9 K (+31.63 %) |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Shea Thomas A. | Chief Financial Off ... | Option Exercise | M | 0.00 | 3,073 | 0 | 9,217 | |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Shea Thomas A. | Chief Financial Off ... | Option Exercise | M | 0.00 | 1,044 | 0 | 0 | |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Shea Thomas A. | Chief Financial Off ... | Payment of Exercise | F | 2.80 | 1,554 | 4,351 | 31,489 | 33 K to 31.5 K (-4.70 %) |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Shea Thomas A. | Chief Financial Off ... | Buy | M | 0.00 | 3,073 | 0 | 33,043 | 30 K to 33 K (+10.25 %) |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Shea Thomas A. | Chief Financial Off ... | Buy | M | 0.00 | 1,044 | 0 | 29,970 | 28.9 K to 30 K (+3.61 %) |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Option Exercise | M | 0.00 | 9,887 | 0 | 29,661 | |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Option Exercise | M | 0.00 | 1,519 | 0 | 0 | |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Payment of Exercise | F | 2.80 | 4,305 | 12,054 | 177,083 | 181.4 K to 177.1 K (-2.37 %) |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Buy | M | 0.00 | 9,887 | 0 | 181,388 | 171.5 K to 181.4 K (+5.76 %) |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Buy | M | 0.00 | 1,519 | 0 | 171,501 | 170 K to 171.5 K (+0.89 %) |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | Chief Technical Off ... | Option Exercise | M | 0.00 | 2,608 | 0 | 7,824 | |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | Chief Technical Off ... | Option Exercise | M | 0.00 | 1,044 | 0 | 0 | |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | Chief Technical Off ... | Payment of Exercise | F | 2.80 | 1,379 | 3,861 | 32,661 | 34 K to 32.7 K (-4.05 %) |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | Chief Technical Off ... | Buy | M | 0.00 | 2,608 | 0 | 34,040 | 31.4 K to 34 K (+8.30 %) |
Mar 01 2016 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | Chief Technical Off ... | Buy | M | 0.00 | 1,044 | 0 | 31,432 | 30.4 K to 31.4 K (+3.44 %) |
Dec 22 2015 | CRXX | EPIRUS Biopharmace ... | Ticktin Robert | General Counsel | Buy | P | 3.72 | 3,000 | 11,162 | 3,000 | 0 to 3 K |
Dec 21 2015 | CRXX | EPIRUS Biopharmace ... | Vincent Aurentz | Chief Business Offi ... | Buy | P | 3.43 | 2,200 | 7,546 | 2,200 | 0 to 2.2 K |
Dec 17 2015 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Buy | P | 2.80 | 8,270 | 23,156 | 169,982 | 161.7 K to 170 K (+5.11 %) |
Dec 16 2015 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Buy | P | 2.87 | 8,069 | 23,158 | 161,712 | 153.6 K to 161.7 K (+5.25 %) |
Dec 11 2015 | CRXX | EPIRUS Biopharmace ... | Vincent Aurentz | Chief Business Offi ... | Buy | P | 3.85 | 2,800 | 10,780 | 2,800 | 0 to 2.8 K |
Dec 10 2015 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Buy | P | 4.07 | 13,190 | 53,683 | 153,643 | 140.5 K to 153.6 K (+9.39 %) |
Nov 10 2015 | CRXX | EPIRUS Biopharmace ... | Vincent Aurentz | Chief Business Offi ... | Option Exercise | A | 5.21 | 219,487 | 1,143,527 | 219,487 | |
Nov 03 2015 | CRXX | EPIRUS Biopharmace ... | Shea Thomas A. | Chief Financial Off ... | Option Exercise | M | 1.30 | 28,926 | 37,604 | 20,662 | |
Nov 03 2015 | CRXX | EPIRUS Biopharmace ... | Shea Thomas A. | Chief Financial Off ... | Buy | M | 1.30 | 28,926 | 37,604 | 28,926 | 0 to 28.9 K |
Nov 03 2015 | CRXX | EPIRUS Biopharmace ... | Ticktin Robert | General Counsel | Option Exercise | A | 5.55 | 39,474 | 219,081 | 39,474 | |
Nov 03 2015 | CRXX | EPIRUS Biopharmace ... | Shea Thomas A. | Chief Financial Off ... | Option Exercise | A | 5.55 | 56,842 | 315,473 | 56,842 | |
Nov 03 2015 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | Chief Technical Off ... | Option Exercise | A | 5.55 | 58,247 | 323,271 | 58,247 | |
Nov 03 2015 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Option Exercise | A | 5.55 | 199,537 | 1,107,430 | 199,537 | |
Sep 22 2015 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Buy | P | 6.19 | 10,000 | 61,900 | 140,453 | 130.5 K to 140.5 K (+7.67 %) |
Sep 21 2015 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Buy | P | 5.99 | 10,000 | 59,860 | 130,453 | 120.5 K to 130.5 K (+8.30 %) |
Sep 14 2015 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | Chief Technical Off ... | Option Exercise | M | 1.00 | 4,538 | 4,538 | 2,269 | |
Sep 14 2015 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | Chief Technical Off ... | Option Exercise | M | 1.00 | 4,209 | 4,209 | 3,880 | |
Sep 14 2015 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | Chief Technical Off ... | Buy | M | 1.00 | 8,747 | 8,747 | 30,388 | 21.6 K to 30.4 K (+40.42 %) |
Jul 06 2015 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Option Exercise | M | 1.00 | 22,681 | 22,681 | 14,860 | |
Jul 06 2015 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Option Exercise | M | 1.00 | 7,246 | 7,246 | 18,639 | |
Jul 06 2015 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Option Exercise | M | 1.00 | 21,273 | 21,273 | 43,397 | |
Jul 06 2015 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Buy | M | 1.00 | 51,200 | 51,200 | 120,453 | 69.3 K to 120.5 K (+73.93 %) |
Jun 08 2015 | CRXX | EPIRUS Biopharmace ... | ROCKLAGE SCOTT M | Director | Option Exercise | A | 6.39 | 9,000 | 57,510 | 9,000 | |
Jun 08 2015 | CRXX | EPIRUS Biopharmace ... | McHugh Julie | Director | Option Exercise | A | 6.39 | 9,000 | 57,510 | 9,000 | |
Jun 08 2015 | CRXX | EPIRUS Biopharmace ... | Hunter William L | Director | Option Exercise | A | 6.39 | 9,000 | 57,510 | 9,000 | |
Jun 08 2015 | CRXX | EPIRUS Biopharmace ... | Fu Daotian | Director | Option Exercise | A | 6.39 | 9,000 | 57,510 | 9,000 | |
Jun 08 2015 | CRXX | EPIRUS Biopharmace ... | DUYK GEOFFREY M | Director | Option Exercise | A | 6.39 | 9,000 | 57,510 | 9,000 | |
Jun 08 2015 | CRXX | EPIRUS Biopharmace ... | CORRIGAN MARK | Director | Option Exercise | A | 6.39 | 9,000 | 57,510 | 9,000 | |
Jun 08 2015 | CRXX | EPIRUS Biopharmace ... | BUCHI J KEVIN | Director | Option Exercise | A | 6.39 | 9,000 | 57,510 | 9,000 | |
Apr 03 2015 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | Chief Technical Off ... | Option Exercise | A | 8.40 | 20,000 | 168,000 | 20,000 | |
Mar 02 2015 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | See Remarks | Option Exercise | A | 0.00 | 10,432 | 0 | 10,432 | |
Mar 02 2015 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | See Remarks | Option Exercise | A | 0.00 | 1,044 | 0 | 1,044 | |
Mar 02 2015 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | See Remarks | Option Exercise | A | 10.53 | 79,461 | 836,724 | 79,461 | |
Mar 02 2015 | CRXX | EPIRUS Biopharmace ... | Shea Thomas A. | Chief Financial Off ... | Option Exercise | A | 0.00 | 12,290 | 0 | 12,290 | |
Mar 02 2015 | CRXX | EPIRUS Biopharmace ... | Shea Thomas A. | Chief Financial Off ... | Option Exercise | A | 0.00 | 1,044 | 0 | 1,044 | |
Mar 02 2015 | CRXX | EPIRUS Biopharmace ... | Shea Thomas A. | Chief Financial Off ... | Option Exercise | A | 10.53 | 93,609 | 985,703 | 93,609 | |
Mar 02 2015 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Option Exercise | A | 0.00 | 39,548 | 0 | 39,548 | |
Mar 02 2015 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Option Exercise | A | 0.00 | 1,519 | 0 | 1,519 | |
Mar 02 2015 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Off ... | Option Exercise | A | 10.53 | 301,225 | 3,171,899 | 301,225 | |
Mar 02 2015 | CRXX | EPIRUS Biopharmace ... | Ticktin Robert | General Counsel | Option Exercise | A | 0.00 | 8,534 | 0 | 8,534 | |
Mar 02 2015 | CRXX | EPIRUS Biopharmace ... | Ticktin Robert | General Counsel | Option Exercise | A | 0.00 | 949 | 0 | 949 | |
Mar 02 2015 | CRXX | EPIRUS Biopharmace ... | Ticktin Robert | General Counsel | Option Exercise | A | 10.53 | 65,006 | 684,513 | 65,006 | |
Feb 09 2015 | CRXX | EPIRUS Biopharmace ... | MONTREUX EQUITY PARTNERS IV LP | 10% Owner | Sell | S | 5.01 | 100,000 | 500,930 | 1,671,400 | 1.8 M to 1.7 M (-5.65 %) |
Feb 09 2015 | CRXX | EPIRUS Biopharmace ... | MONTREUX EQUITY PARTNERS IV LP | 10% Owner | Sell | S | 4.97 | 67,316 | 334,843 | 1,771,400 | 1.8 M to 1.8 M (-3.66 %) |
Feb 06 2015 | CRXX | EPIRUS Biopharmace ... | 5AM Partners III, LLC | 10% Owner | Buy | P | 5.00 | 389,950 | 1,949,750 | 2,549,211 | 2.2 M to 2.5 M (+18.06 %) |
Feb 06 2015 | CRXX | EPIRUS Biopharmace ... | 5AM Partners III, LLC | 10% Owner | Buy | P | 5.00 | 10,050 | 50,250 | 65,699 | 55.6 K to 65.7 K (+18.06 %) |
Feb 06 2015 | CRXX | EPIRUS Biopharmace ... | ROCKLAGE SCOTT M | Director | Buy | P | 5.00 | 389,950 | 1,949,750 | 2,549,211 | 2.2 M to 2.5 M (+18.06 %) |
Feb 06 2015 | CRXX | EPIRUS Biopharmace ... | ROCKLAGE SCOTT M | Director | Buy | P | 5.00 | 10,050 | 50,250 | 65,699 | 55.6 K to 65.7 K (+18.06 %) |
Feb 05 2015 | CRXX | EPIRUS Biopharmace ... | MONTREUX EQUITY PARTNERS IV LP | 10% Owner | Sell | S | 4.95 | 5,684 | 28,139 | 1,838,716 | 1.8 M to 1.8 M (-0.31 %) |
Feb 05 2015 | CRXX | EPIRUS Biopharmace ... | MONTREUX EQUITY PARTNERS IV LP | 10% Owner | Sell | S | 4.99 | 47,000 | 234,431 | 1,844,400 | 1.9 M to 1.8 M (-2.48 %) |
Jan 28 2015 | CRXX | EPIRUS Biopharmace ... | MONTREUX EQUITY PARTNERS IV LP | 10% Owner | Sell | S | 6.47 | 38,516 | 249,102 | 1,891,400 | 1.9 M to 1.9 M (-2.00 %) |
Jan 26 2015 | CRXX | EPIRUS Biopharmace ... | MONTREUX EQUITY PARTNERS IV LP | 10% Owner | Sell | S | 6.27 | 8,400 | 52,699 | 1,929,916 | 1.9 M to 1.9 M (-0.43 %) |
Jan 26 2015 | CRXX | EPIRUS Biopharmace ... | MONTREUX EQUITY PARTNERS IV LP | 10% Owner | Sell | S | 6.30 | 14,130 | 88,979 | 1,938,316 | 2 M to 1.9 M (-0.72 %) |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | BUCHI J KEVIN | Director | Option Exercise | A | 1.30 | 13,259 | 17,237 | 13,259 | |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | CORRIGAN MARK | Director | Payment of Exercise | F | 11.80 | 14,597 | 172,245 | 21,859 | 36.5 K to 21.9 K (-40.04 %) |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Of ... | Option Exercise | A | 7.40 | 332,694 | 2,461,936 | 332,694 | |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Of ... | Option Exercise | A | 1.00 | 37,541 | 37,541 | 37,541 | |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Of ... | Option Exercise | A | 1.00 | 25,885 | 25,885 | 25,885 | |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Of ... | Option Exercise | A | 1.00 | 64,670 | 64,670 | 64,670 | |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | Munshi Amit | Chief Executive Of ... | Grant | A | 0.00 | 69,253 | 0 | 69,253 | 0 to 69.3 K |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | Ticktin Robert | General Counsel | Option Exercise | A | 11.48 | 99,442 | 1,141,594 | 99,442 | |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | See Remarks | Option Exercise | A | 7.40 | 86,448 | 639,715 | 86,448 | |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | See Remarks | Option Exercise | A | 1.00 | 6,807 | 6,807 | 6,807 | |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | See Remarks | Option Exercise | A | 1.00 | 8,089 | 8,089 | 8,089 | |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | See Remarks | Option Exercise | A | 1.00 | 20,209 | 20,209 | 20,209 | |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | Wyand Michael | See Remarks | Grant | A | 0.00 | 21,641 | 0 | 21,641 | 0 to 21.6 K |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | Seth Kim | Chief Business Offi ... | Option Exercise | A | 7.40 | 94,138 | 696,621 | 94,138 | |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | Seth Kim | Chief Business Offi ... | Option Exercise | A | 5.80 | 49,058 | 284,536 | 49,058 | |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | Hunter William L | Director | Option Exercise | A | 11.48 | 13,259 | 152,213 | 13,259 | |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | McHugh Julie | Director | Option Exercise | A | 11.48 | 13,259 | 152,213 | 13,259 | |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | Shea Thomas A. | Chief Financial Off ... | Option Exercise | A | 7.40 | 93,608 | 692,699 | 93,608 | |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | Shea Thomas A. | Chief Financial Off ... | Option Exercise | A | 1.30 | 49,588 | 64,464 | 49,588 | |
Jul 17 2014 | CRXX | EPIRUS Biopharmace ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Buy | J | 0.00 | 22,239,223 | 0 | 22,239,223 | 0 to 22.2 M |
Feb 12 2014 | CRXX | EPIRUS Biopharmace ... | Renz Justin A | EVP, CFO & Treasure ... | Grant | A | 0.00 | 250,000 | 0 | 250,000 | 0 to 250 K |
Feb 12 2014 | CRXX | EPIRUS Biopharmace ... | CORRIGAN MARK | President & CEO | Option Exercise | A | 1.47 | 250,000 | 367,500 | 250,000 | |
Feb 12 2014 | CRXX | EPIRUS Biopharmace ... | CORRIGAN MARK | President & CEO | Grant | A | 0.00 | 250,000 | 0 | 364,567 | 114.6 K to 364.6 K (+218.21 %) |
Jan 17 2014 | CRXX | EPIRUS Biopharmace ... | CORRIGAN MARK | President & CEO | Payment of Exercise | F | 1.66 | 18,079 | 30,011 | 114,567 | 132.6 K to 114.6 K (-13.63 %) |
Jan 07 2014 | CRXX | EPIRUS Biopharmace ... | CORRIGAN MARK | President & CEO | Payment of Exercise | F | 1.22 | 8,035 | 9,803 | 132,646 | 140.7 K to 132.6 K (-5.71 %) |
Jun 10 2013 | CRXX | EPIRUS Biopharmace ... | OSHEA WILLIAM J | Director | Option Exercise | A | 0.58 | 15,000 | 8,700 | 15,000 | |
Jun 10 2013 | CRXX | EPIRUS Biopharmace ... | Kauffman Michael | Director | Option Exercise | A | 0.58 | 15,000 | 8,700 | 15,000 | |
Jun 10 2013 | CRXX | EPIRUS Biopharmace ... | Hunter William L | Director | Option Exercise | A | 0.58 | 15,000 | 8,700 | 15,000 | |
Jun 10 2013 | CRXX | EPIRUS Biopharmace ... | CRAWFORD SALLY | Director | Option Exercise | A | 0.58 | 15,000 | 8,700 | 15,000 | |
Jun 10 2013 | CRXX | EPIRUS Biopharmace ... | HAYDU FRANK | Director | Option Exercise | A | 0.58 | 15,000 | 8,700 | 15,000 | |
Jan 17 2013 | CRXX | EPIRUS Biopharmace ... | CORRIGAN MARK | President & CEO | Sell | S | 0.77 | 112,850 | 86,895 | 844,090 | 956.9 K to 844.1 K (-11.79 %) |
Jan 07 2013 | CRXX | EPIRUS Biopharmace ... | Cole Jason | EVP,Corp Dev & Gene ... | Option Exercise | A | 0.76 | 280,000 | 212,800 | 280,000 | |
Jan 07 2013 | CRXX | EPIRUS Biopharmace ... | Renz Justin A | EVP, CFO & Treasure ... | Option Exercise | A | 0.76 | 280,000 | 212,800 | 280,000 | |
Jan 07 2013 | CRXX | EPIRUS Biopharmace ... | CORRIGAN MARK | President & CEO | Option Exercise | A | 0.76 | 500,000 | 380,000 | 500,000 | |
Jan 07 2013 | CRXX | EPIRUS Biopharmace ... | CORRIGAN MARK | President & CEO | Grant | A | 0.00 | 250,000 | 0 | 956,940 | 706.9 K to 956.9 K (+35.36 %) |
May 25 2012 | CRXX | EPIRUS Biopharmace ... | OSHEA WILLIAM J | Director | Option Exercise | A | 0.76 | 15,000 | 11,400 | 15,000 | |
May 25 2012 | CRXX | EPIRUS Biopharmace ... | Kauffman Michael | Director | Option Exercise | A | 0.76 | 15,000 | 11,400 | 15,000 | |
May 25 2012 | CRXX | EPIRUS Biopharmace ... | Hunter William L | Director | Option Exercise | A | 0.76 | 15,000 | 11,400 | 15,000 | |
May 25 2012 | CRXX | EPIRUS Biopharmace ... | HAYDU FRANK | Director | Option Exercise | A | 0.76 | 15,000 | 11,400 | 15,000 | |
May 25 2012 | CRXX | EPIRUS Biopharmace ... | Foley Todd | Director | Option Exercise | A | 0.76 | 15,000 | 11,400 | 15,000 | |
May 25 2012 | CRXX | EPIRUS Biopharmace ... | CRAWFORD SALLY | Director | Option Exercise | A | 0.76 | 15,000 | 11,400 | 15,000 | |
Feb 29 2012 | CRXX | EPIRUS Biopharmace ... | Gallen Christopher C. | EVP Research & Deve ... | Grant | A | 0.00 | 350,000 | 0 | 1,842,986 | 1.5 M to 1.8 M (+23.44 %) |
Jan 27 2012 | CRXX | EPIRUS Biopharmace ... | Gallen Christopher C. | EVP Research & Deve ... | Option Exercise | A | 1.13 | 53,692 | 60,672 | 53,692 | |
Jan 27 2012 | CRXX | EPIRUS Biopharmace ... | Gallen Christopher C. | EVP Research & Deve ... | Option Exercise | A | 1.13 | 271,308 | 306,578 | 271,308 | |
Jan 31 2012 | CRXX | EPIRUS Biopharmace ... | Cole Jason | SVP & General Couns ... | Sell | S | 1.09 | 2,420 | 2,638 | 15,086 | 17.5 K to 15.1 K (-13.82 %) |
Jan 27 2012 | CRXX | EPIRUS Biopharmace ... | Renz Justin A | SVP, CFO & Treasure ... | Option Exercise | A | 1.13 | 313,121 | 353,827 | 313,121 | |
Jan 27 2012 | CRXX | EPIRUS Biopharmace ... | Renz Justin A | SVP, CFO & Treasure ... | Option Exercise | A | 1.13 | 111,879 | 126,423 | 111,879 | |
Jan 27 2012 | CRXX | EPIRUS Biopharmace ... | Cole Jason | SVP & General Couns ... | Option Exercise | A | 1.13 | 242,809 | 274,374 | 242,809 | |
Jan 27 2012 | CRXX | EPIRUS Biopharmace ... | Cole Jason | SVP & General Couns ... | Option Exercise | A | 1.13 | 107,191 | 121,126 | 107,191 | |
Jan 27 2012 | CRXX | EPIRUS Biopharmace ... | CORRIGAN MARK | President & CEO | Option Exercise | A | 1.13 | 799,226 | 903,125 | 799,226 | |
Jan 27 2012 | CRXX | EPIRUS Biopharmace ... | CORRIGAN MARK | President & CEO | Option Exercise | A | 1.13 | 100,774 | 113,875 | 100,774 | |
Jan 19 2012 | CRXX | EPIRUS Biopharmace ... | CORRIGAN MARK | President & CEO | Sell | S | 1.14 | 68,105 | 77,640 | 706,940 | 775 K to 706.9 K (-8.79 %) |
Oct 28 2011 | CRXX | EPIRUS Biopharmace ... | EVNIN LUKE | 10% Owner | Sell | S | 1.03 | 738,807 | 760,971 | 11,133,961 | 11.9 M to 11.1 M (-6.22 %) |
Oct 28 2011 | CRXX | EPIRUS Biopharmace ... | MPM BIOVENTURES III LLC | 10% Owner | Sell | S | 1.03 | 738,807 | 760,971 | 11,133,961 | 11.9 M to 11.1 M (-6.22 %) |
Oct 27 2011 | CRXX | EPIRUS Biopharmace ... | EVNIN LUKE | 10% Owner | Sell | S | 1.02 | 78,000 | 79,560 | 11,872,768 | 12 M to 11.9 M (-0.65 %) |
Oct 27 2011 | CRXX | EPIRUS Biopharmace ... | EVNIN LUKE | 10% Owner | Sell | S | 1.02 | 203,200 | 207,264 | 11,950,768 | 12.2 M to 12 M (-1.67 %) |
Oct 27 2011 | CRXX | EPIRUS Biopharmace ... | MPM BIOVENTURES III LLC | 10% Owner | Sell | S | 1.02 | 78,000 | 79,560 | 11,872,768 | 12 M to 11.9 M (-0.65 %) |
Oct 27 2011 | CRXX | EPIRUS Biopharmace ... | MPM BIOVENTURES III LLC | 10% Owner | Sell | S | 1.02 | 203,200 | 207,264 | 11,950,768 | 12.2 M to 12 M (-1.67 %) |
Oct 25 2011 | CRXX | EPIRUS Biopharmace ... | MPM BIOVENTURES III LLC | 10% Owner | Sell | S | 1.03 | 252,000 | 259,560 | 12,153,968 | 12.4 M to 12.2 M (-2.03 %) |
Oct 25 2011 | CRXX | EPIRUS Biopharmace ... | MPM BIOVENTURES III LLC | 10% Owner | Sell | S | 1.02 | 70,100 | 71,502 | 12,405,968 | 12.5 M to 12.4 M (-0.56 %) |
Oct 25 2011 | CRXX | EPIRUS Biopharmace ... | EVNIN LUKE | 10% Owner | Sell | S | 1.03 | 252,000 | 259,560 | 12,153,968 | 12.4 M to 12.2 M (-2.03 %) |
Oct 25 2011 | CRXX | EPIRUS Biopharmace ... | EVNIN LUKE | 10% Owner | Sell | S | 1.02 | 70,100 | 71,502 | 12,405,968 | 12.5 M to 12.4 M (-0.56 %) |
Oct 21 2011 | CRXX | EPIRUS Biopharmace ... | EVNIN LUKE | 10% Owner | Sell | S | 1.03 | 425,000 | 437,750 | 12,476,068 | 12.9 M to 12.5 M (-3.29 %) |
Oct 21 2011 | CRXX | EPIRUS Biopharmace ... | EVNIN LUKE | 10% Owner | Sell | S | 1.02 | 34,817 | 35,513 | 12,901,068 | 12.9 M to 12.9 M (-0.27 %) |
Oct 21 2011 | CRXX | EPIRUS Biopharmace ... | MPM BIOVENTURES III LLC | 10% Owner | Sell | S | 1.03 | 425,000 | 437,750 | 12,476,068 | 12.9 M to 12.5 M (-3.29 %) |
Oct 21 2011 | CRXX | EPIRUS Biopharmace ... | MPM BIOVENTURES III LLC | 10% Owner | Sell | S | 1.02 | 34,817 | 35,513 | 12,901,068 | 12.9 M to 12.9 M (-0.27 %) |
Oct 19 2011 | CRXX | EPIRUS Biopharmace ... | EVNIN LUKE | 10% Owner | Sell | S | 1.02 | 19,644 | 20,037 | 12,935,885 | 13 M to 12.9 M (-0.15 %) |
Oct 19 2011 | CRXX | EPIRUS Biopharmace ... | MPM BIOVENTURES III LLC | 10% Owner | Sell | S | 1.02 | 19,644 | 20,037 | 12,935,885 | 13 M to 12.9 M (-0.15 %) |
Oct 17 2011 | CRXX | EPIRUS Biopharmace ... | MPM BIOVENTURES III LLC | 10% Owner | Sell | S | 1.02 | 39,700 | 40,494 | 12,955,529 | 13 M to 13 M (-0.31 %) |
Oct 17 2011 | CRXX | EPIRUS Biopharmace ... | MPM BIOVENTURES III LLC | 10% Owner | Sell | S | 1.02 | 5,000 | 5,100 | 12,995,229 | 13 M to 13 M (-0.04 %) |
Oct 17 2011 | CRXX | EPIRUS Biopharmace ... | EVNIN LUKE | 10% Owner | Sell | S | 1.02 | 39,700 | 40,494 | 12,955,529 | 13 M to 13 M (-0.31 %) |
Oct 17 2011 | CRXX | EPIRUS Biopharmace ... | EVNIN LUKE | 10% Owner | Sell | S | 1.02 | 5,000 | 5,100 | 12,995,229 | 13 M to 13 M (-0.04 %) |
Oct 13 2011 | CRXX | EPIRUS Biopharmace ... | MPM BIOVENTURES III LLC | 10% Owner | Sell | S | 102.00 | 131,800 | 13,443,600 | 13,000,229 | 13.1 M to 13 M (-1.00 %) |
Oct 13 2011 | CRXX | EPIRUS Biopharmace ... | MPM BIOVENTURES III LLC | 10% Owner | Sell | S | 1.02 | 206,500 | 210,630 | 13,132,029 | 13.3 M to 13.1 M (-1.55 %) |